Skip to main content
Amit Agarwal, MD, Oncology, New York, NY

Amit Balkrishna Agarwal MD

Hematologic Oncology


Physician

Join to View Full Profile
  • 1 Gustave L Levy PlNew York, NY 10029

  • Phone+1 212-659-6500

Dr. Agarwal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2010 - 2013
  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2008 - 2010
  • Other
    OtherClass of 2001

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2017 - 2026
  • AZ State Medical License
    AZ State Medical License 2010 - 2022
  • CO State Medical License
    CO State Medical License 2017 - 2019
  • NV State Medical License
    NV State Medical License 2017 - 2019
  • CA State Medical License
    CA State Medical License 2017 - 2018
  • CT State Medical License
    CT State Medical License 2017 - 2018
  • PA State Medical License
    PA State Medical License 2008 - 2018
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma
    Amit Agarwal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
    Amit Agarwal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect¬ MM Registry
    Amit Agarwal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • Arch Oncology Snares AbbVie, BMS, Xencor Execs to Boost Medical, Clinical Management
    Arch Oncology Snares AbbVie, BMS, Xencor Execs to Boost Medical, Clinical ManagementAugust 2nd, 2021
  • Amazon Data Showed Big Jump in Diversity Among Senior Leaders — After Definition of ‘Executive’ Was Loosened
    Amazon Data Showed Big Jump in Diversity Among Senior Leaders — After Definition of ‘Executive’ Was LoosenedMay 25th, 2021

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: